...
首页> 外文期刊>Experimental and therapeutic medicine >The urotensin II receptor antagonist, urantide, protects against atherosclerosis in rats
【24h】

The urotensin II receptor antagonist, urantide, protects against atherosclerosis in rats

机译:urotensin II受体拮抗剂urantide可预防大鼠的动脉粥样硬化

获取原文
获取原文并翻译 | 示例

摘要

The aim of this study was to explore the use of urantide as an antagonist of the urotensin II (UII) receptor, G protein-coupled receptor 14 (GPR14), to protect against atherosclerosis (AS) in rats. The AS rat model was induced by an intraperitoneal injection of vitamin D3 (VD3) into rats fed with a high-fat diet for four weeks. Urantide was then injected into the rats. Immunohistochemical staining, serum biochemical assay, reverse transcription-polymerase chain reaction (RT-PCR) and western blotting were used to investigate the expression of UII and its receptor GPR14 in the AS rat model. Four weeks after induction, pathological changes typical of AS were observed in the AS rat model. In the plaques of the aortic tunica intima and tunica media, expression of UII and GPR14 was observed. The protein and gene expression levels of UII and GPR14 in the model group were significantly increased compared with those in the normal group (P<0.01). Urantide ameliorated the pathological changes of AS in the rat model and reduced the gene and protein expression levels of UII and GPR14 (P<0.05 or P<0.01). UII is associated with AS and the UII receptor GPR14-specific antagonist, urantide, demonstrates the ability to protect against AS. Thus, this study provides new insight and experimental theories for the clinical application of urantide to treat AS.
机译:这项研究的目的是探索使用尿嘧啶作为尿素II(UII)受体,G蛋白偶联受体14(GPR14)的拮抗剂,以预防大鼠的动脉粥样硬化(AS)。腹腔注射维生素D3(VD3)到高脂饮食喂养的大鼠中持续4周,从而诱发了AS大鼠模型。然后将乌兰地特注射到大鼠中。免疫组织化学染色,血清生化分析,逆转录聚合酶链反应(RT-PCR)和蛋白质印迹法研究UII及其受体GPR14在AS大鼠模型中的表达。诱导后四周,在AS大鼠模型中观察到典型的AS病理变化。在主动脉内膜和中膜的斑块中,观察到UII和GPR14的表达。模型组UII和GPR14蛋白和基因表达水平较正常组明显升高(P <0.01)。 Urantide改善了大鼠模型AS的病理变化,降低了UII和GPR14的基因和蛋白质表达水平(P <0.05或P <0.01)。 UII与AS相关,UII受体GPR14特异性拮抗剂urantide具有抵抗AS的能力。因此,本研究为乌兰肽治疗AS的临床应用提供了新的见识和实验理论。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号